Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

ClinicalTrials.gov ID: NCT01435720

Public ClinicalTrials.gov record NCT01435720. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 13, 2026, 5:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies

Study identification

NCT ID: NCT01435720
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Senesco Technologies, Inc.; Industry
Enrollment: 15 participants

Conditions and interventions

Conditions

Interventions

SNS01-T Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2011
Primary completion: Sep 30, 2014
Completion: Nov 30, 2014
Last update posted: Sep 10, 2014

2011 – 2014

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
The University of Arkansas for Medical Sciences	Little Rock	Arkansas	72205	—
Mayo Clinic	Rochester	Minnesota	55905	—
Hackensack University Medical Center	Hackensack	New Jersey	07601	—
Fred Hutchinson Cancer Research Center/University of Washington Medical Center	Seattle	Washington	98109	—
West Virginia University Mary Babb Randolf Cancer Center	Morgantown	West Virginia	26506	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01435720, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 10, 2014 · Synced May 13, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01435720 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →